Bionomics Investor Presentation Deck
Merck & Co Strategic Collaboration: Positive Allosteric Modulators (PAMS) of a7 Receptor
a7 Receptor PAMs correct hypocholinergic states in cognitive dysfunction and impairment
MERCK
PARTNERSHIP
Bionomics
MSD Collaboration Overview
2014 agreement to develop a7 receptor PAMS targeting cognitive dysfunction associated with
Alzheimer's disease, schizophrenia and other CNS conditions
✓
Merck funds all research and clinical development, and WW commercialization of any resulting
products
✓
✓
Payments received: US$20M upfront and US$10M for Phase 1 milestone
Eligible to receive up to US$465M in additional milestone payments plus royalties
Development Updates
Two candidate a7 receptor PAMs in early-stage Phase 1 safety and biomarker clinical trials for
cognitive impairment
✓
1st compound has completed Phase 1 safety clinical trials in healthy subjects with ongoing plans for
further biomarker studies
12
✓
In 2020, a second molecule showed an improved potency profile in preclinical animal models and was
advanced by Merck into Phase 1 clinical trials
Wang et al. J Pharmacol Exp Ther 373:311-324, May 2020 https://pubmed.ncbi.nlm.nih.gov/32094294/
PAM = Positive allosteric modulator
MSD = A tradename of Merck & Co., Inc., Kenilworth NJ USAView entire presentation